AG真人官方

STOCK TITAN

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags

Biogen (BIIB) has announced plans for a new global headquarters at Kendall Common in Cambridge, Massachusetts, signing a 15-year lease for approximately 580,000-square-feet of office and research space. The state-of-the-art facility, scheduled to open in 2028 coinciding with Biogen's 50th anniversary, will serve as an innovation hub integrating research, development, technical operations, and commercial teams.

The company will be the sole corporate tenant in the building, which is being developed through a joint venture between MIT Investment Management Company and BioMed AG真人官方ty. The facility will feature modern laboratories, upgraded workspaces, sustainable design elements, and the Biogen CoLab - a community laboratory space for collaboration with nonprofits, schools, and universities.

Biogen (BIIB) ha annunciato piani per una nuova sede globale a Kendall Common a Cambridge, Massachusetts, firmando un contratto di locazione di 15 anni per circa 54.000 metri quadrati di uffici e spazi di ricerca. La struttura all'avanguardia, prevista per l'apertura nel 2028 in coincidenza con il 50掳 anniversario di Biogen, funger脿 da hub di innovazione integrando ricerca, sviluppo, operazioni tecniche e team commerciali.

L'azienda sar脿 l'unico inquilino aziendale dell'edificio, che 猫 in fase di sviluppo attraverso una joint venture tra MIT Investment Management Company e BioMed AG真人官方ty. La struttura presenter脿 laboratori moderni, spazi di lavoro aggiornati, elementi di design sostenibile e il Biogen CoLab - uno spazio di laboratorio comunitario per la collaborazione con organizzazioni no-profit, scuole e universit脿.

Biogen (BIIB) ha anunciado planes para una nueva sede global en Kendall Common en Cambridge, Massachusetts, firmando un contrato de arrendamiento de 15 a帽os para aproximadamente 54,000 pies cuadrados de espacio de oficinas e investigaci贸n. La instalaci贸n de 煤ltima generaci贸n, programada para abrir en 2028 coincidiendo con el 50 aniversario de Biogen, servir谩 como un centro de innovaci贸n integrando investigaci贸n, desarrollo, operaciones t茅cnicas y equipos comerciales.

La compa帽铆a ser谩 el 煤nico inquilino corporativo en el edificio, que est谩 siendo desarrollado a trav茅s de una empresa conjunta entre MIT Investment Management Company y BioMed AG真人官方ty. La instalaci贸n contar谩 con laboratorios modernos, espacios de trabajo mejorados, elementos de dise帽o sostenible y el Biogen CoLab - un espacio de laboratorio comunitario para la colaboraci贸n con organizaciones sin fines de lucro, escuelas y universidades.

Biogen (BIIB)電� 毵れ偓於旍劯旄犾< 旌犽笇毽鞚� Kendall Common鞐� 靸堧鞖� 旮搿滊矊 氤胳偓毳� 靹り硠頃橁碃, 鞎� 54,000 鞝滉潮氙疙劙鞚� 靷鞁� 氚� 鞐瓣惮 瓿店皠鞐� 雽頃� 15雲� 鞛勲寑 瓿勳暯鞚� 觳搓舶頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. 斓滌波雼� 鞁滌劋鞚 Biogen鞚� 50欤茧厔 旮半厫鞚缄臣 鞚检箻頃橂姅 2028雲勳棎 臧滌灔頃� 鞓堨爼鞚措┌, 鞐瓣惮, 臧滊皽, 旮办垹 鞖挫榿 氚� 靸侅梾 韺鞚� 韱淀暕頃橂姅 順侅嫚 項堧笇 鞐暊鞚� 頃� 瓴冹瀰雼堧嫟.

須岇偓電� 頃措嫻 瓯措鞚� 鞙犾澕頃� 旮办梾 鞛勳皑鞚胳澊氅�, MIT 韴瀽 甏毽� 須岇偓鞕 BioMed AG真人官方ty 臧勳潣 頃╈瀾 韴瀽搿� 臧滊皽霅橁碃 鞛堨姷雼堧嫟. 鞚� 鞁滌劋鞚 順勲寑鞝侅澑 鞁ろ棙鞁�, 鞐呹犯霠堨澊霌滊悳 鞛戩梾 瓿店皠, 歆靻� 臧電ロ暅 霐旍瀽鞚� 鞖旍唽 氚� 牍勳榿毽� 雼泊, 頃欔祼 氚� 雽頃欔臣 順戩梾頃橂姅 旎る雼堩嫲 鞁ろ棙鞁� 瓿店皠鞚� Biogen CoLab鞚� 韸轨鞙茧 頃� 瓴冹瀰雼堧嫟.

Biogen (BIIB) a annonc茅 des projets pour un nouveau si猫ge mondial 脿 Kendall Common 脿 Cambridge, Massachusetts, signant un bail de 15 ans pour environ 54 000 pieds carr茅s d'espace de bureau et de recherche. L'installation 脿 la pointe de la technologie, pr茅vue pour ouvrir en 2028 en co茂ncidence avec le 50e anniversaire de Biogen, servira de centre d'innovation int茅grant recherche, d茅veloppement, op茅rations techniques et 茅quipes commerciales.

L'entreprise sera le seul locataire d'entreprise dans le b芒timent, qui est en cours de d茅veloppement par le biais d'une coentreprise entre la MIT Investment Management Company et BioMed AG真人官方ty. L'installation comprendra des laboratoires modernes, des espaces de travail am茅lior茅s, des 茅l茅ments de conception durable et le Biogen CoLab - un espace de laboratoire communautaire pour la collaboration avec des organisations 脿 but non lucratif, des 茅coles et des universit茅s.

Biogen (BIIB) hat Pl盲ne f眉r eine neue globale Hauptzentrale in Kendall Common in Cambridge, Massachusetts, angek眉ndigt und einen 15-j盲hrigen Mietvertrag f眉r etwa 54.000 Quadratmeter B眉ro- und Forschungsfl盲che unterzeichnet. Die hochmoderne Einrichtung, die 2028 er枚ffnet werden soll und mit dem 50. Jubil盲um von Biogen zusammenf盲llt, wird als Innovationszentrum fungieren, das Forschung, Entwicklung, technische Abl盲ufe und kommerzielle Teams integriert.

Das Unternehmen wird der einzige Unternehmensmieter in dem Geb盲ude sein, das durch ein Joint Venture zwischen der MIT Investment Management Company und BioMed AG真人官方ty entwickelt wird. Die Einrichtung wird moderne Labore, verbesserte Arbeitsbereiche, nachhaltige Designelemente und das Biogen CoLab - einen Gemeinschaftslaborraum zur Zusammenarbeit mit gemeinn眉tzigen Organisationen, Schulen und Universit盲ten - umfassen.

Positive
  • Consolidation of operations will improve operational efficiency and foster collaboration
  • Strategic location in Kendall Square enhances access to talent and research partnerships
  • Long-term 15-year lease commitment demonstrates stability and growth planning
  • Sole corporate tenant status allows for customized facility optimization
Negative
  • Significant real estate commitment may increase fixed costs
  • Potential disruption during relocation process in 2028
  • Long-term lease creates reduced flexibility in future space planning
  • Biogen signs lease for Kendall Common as part of multi-year real estate optimization plan to modernize its facilities and consolidate its Massachusetts real estate footprint
  • New building will be designed to foster collaboration and spark innovation; Biogen plans to relocate Cambridge-based employees to the new site in 2028

CAMBRIDGE, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Inc. (Nasdaq: BIIB) announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year real estate consolidation plan in Massachusetts. The move centralizes Biogen鈥檚 presence in Kendall Square, integrating Biogen鈥檚 research and development and technical operations teams alongside its global and North American commercial organizations into a co-located innovation hub. Scheduled to open when Biogen celebrates its 50th anniversary in 2028, the new state-of-the-art facility will commemorate five decades of excellence in scientific discovery, clinical development, and delivering innovative new treatments.

鈥淣early 50 years after first putting down roots in Kendall Square, Biogen is embarking on a new chapter in the very heart of the community that has shaped our success,鈥� said Christopher A. Viehbacher, President and Chief Executive Officer at Biogen. 鈥淥ur new space will support the advancement of our pipeline of breakthrough medicines by bringing our employees together and fostering collaboration with leading scientific minds, key partners, and top talent.鈥�

鈥淏iogen has been a foundational presence in the Massachusetts life science ecosystem for close to half a century, and we are thrilled to see them begin a new era in our state,鈥� said Maura Healey, Governor of Massachusetts. 鈥淭his milestone is an example of why Massachusetts remains the center for long-term growth and opportunity in the life sciences. Our administration continues to make investments in the sector in order to help create more companies and jobs that lead to innovative new treatments for patients.鈥�

鈥淚t鈥檚 fitting that Biogen 鈥� a company with such close ties to people at MIT 鈥� will make Kendall Common鈥檚 first building its new home,鈥� said Sally Kornbluth, President of MIT. 鈥淭he motto of Kendall Square might as well be 'talent in proximity' and Biogen's decision to intensify its presence here promises great things for the whole ecosystem. To achieve this milestone on the occasion of the company鈥檚 50th anniversary is especially meaningful. We are grateful to Chris Viehbacher, president and chief executive officer of Biogen, for his keen vision of the future and his ongoing commitment to Cambridge and Kendall Square.鈥�

鈥淢assachusetts is the global leader in biotechnology because Biogen pioneered a scientific revolution decades ago. The decision by Biogen today to develop a new hub here goes to the very core of what makes this ecosystem great: collaboration, talent, and institutions,鈥� said Kendalle Burlin O鈥機onnell, Chief Executive Officer & President of MassBio. 鈥淭his is the place patients around the world look to for lifesaving medicines and with this new facility, Biogen is breaking ground on the future of biomedical innovation and solidifying the Commonwealth鈥檚 dominance in healthcare.鈥�

Biogen has signed a 15-year lease for approximately 580,000-square-feet of office and research and development space as part of the development project. The lease agreement is with a new joint venture partnership between MIT Investment Management Company (MITIMCo) and BioMed AG真人官方ty, a Blackstone AG真人官方 Estate portfolio company, that is developing the new building.

Biogen plans to be the sole corporate tenant in the building, allowing the company to optimize its real estate footprint in Cambridge and create a purpose-built innovation hub designed to foster increased collaboration among employees and external partners. This state-of-the-art facility will feature laboratories of the future, upgraded workspaces, and modern amenities, along with sustainable design elements such as advanced water conservation measures and energy-efficient systems.

In addition, the building will house the Biogen CoLab. The Biogen CoLab is a classroom-style community laboratory and collaborative space where Biogen scientists, nonprofits and schools and universities come together to help students and career-ready adults discover and prepare for careers in life science and healthcare. The Biogen CoLab is intended to serve not only as a gateway to Biogen, but as a central engine of talent generation and dynamic co-creation.

Biogen鈥檚 history in the region can be traced back to the early 1980s when it established its research facility and headquarters in Kendall Square. Cambridge will remain the global headquarters of Biogen, and the company is pleased to be an integral part of the Kendall Square community admired around the world for innovation and creativity, especially in the life sciences.

About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients鈥� lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

We routinely post information that may be important to investors on our website at聽.聽Follow us on social media聽-聽,听, , .

Biogen Safe Harbor聽
This news release contains forward-looking statements, including about the anticipated benefits of the new headquarters, the potential of Biogen's commercial business and pipeline programs; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as 鈥渁im,鈥� 鈥渁nticipate,鈥� 鈥渁ssume,鈥� 鈥渂elieve,鈥� 鈥渃ontemplate,鈥� 鈥渃ontinue,鈥� 鈥渃ould,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渇orecast,鈥� 鈥済oal,鈥� 鈥済uidance,鈥� 鈥渉ope,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渙bjective,鈥� 鈥減lan,鈥� 鈥減ossible,鈥� 鈥減otential,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥減rospect,鈥� 鈥渟hould,鈥� 鈥渢arget,鈥� 鈥渨ill,鈥� 鈥渨ould,鈥� and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission.

These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned 鈥淣ote Regarding Forward-Looking Statements鈥� and 鈥淚tem 1A. Risk Factors,鈥� and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

MEDIA CONTACT:
Biogen
Jack Cox
+1 781 464 3260
[email protected]
INVESTOR CONTACT:
Biogen
Tim Power
+1 781 464 2442
[email protected]

FAQ

When will Biogen (BIIB) move to its new Kendall Square headquarters?

Biogen plans to relocate Cambridge-based employees to the new Kendall Common headquarters in 2028, coinciding with the company's 50th anniversary.

How large is Biogen's (BIIB) new headquarters lease at Kendall Common?

Biogen has signed a 15-year lease for approximately 580,000-square-feet of office and research and development space.

What features will Biogen's (BIIB) new Kendall Square facility include?

The facility will include laboratories of the future, upgraded workspaces, modern amenities, sustainable design elements, and the Biogen CoLab community laboratory.

Who are the development partners for Biogen's (BIIB) new headquarters project?

The building is being developed through a joint venture between MIT Investment Management Company (MITIMCo) and BioMed AG真人官方ty, a Blackstone AG真人官方 Estate portfolio company.
Biogen Inc

NASDAQ:BIIB

BIIB Rankings

BIIB Latest News

BIIB Latest SEC Filings

BIIB Stock Data

18.65B
146.22M
0.21%
94.46%
2.54%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
United States
CAMBRIDGE